Aberrant regulation of FBW7 in cancer

Oncotarget

Volumn 5, Issue 8, 2014, Pages 2000-2015

  Wang, Lixia ^a   Ye, Xiantao ^a   Liu, Yueyong ^b   Wei, Wenyi ^b   Wang, Zhiwei ^a  

^a SOOCHOW UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; FBW7; Oncoprotein; SCF; Tumor suppressor; Ubiquitination

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN DELTA; CYCLIN E; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR 2; MEDIATOR 13; MEDIATOR COMPLEX; MICRORNA; MICRORNA 129 5P; MICRORNA 223; MICRORNA 25; MICRORNA 27A; MYC PROTEIN; NOTCH RECEPTOR; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN C JUN; PROTEIN FBW7; PROTEIN MCL 1; PROTEIN P53; TRANSCRIPTION FACTOR HES 5; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; ENZYME INACTIVATION; ENZYME REGULATION; GENE DELETION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE PROTEINS; F-BOX PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84899515719     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1859     Document Type: Article

References (203)

1. Welcker M and Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008; 8(2):83-93.
2. Minella AC and Clurman BE. Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle. 2005; 4(10):1356-1359.
3. Lau AW, Fukushima H and Wei W. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci. 2012; 17:2197-2212.
4. Crusio KM, King B, Reavie LB and Aifantis I. The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene. 2010; 29(35):4865-4873.
5. Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, Muller-Holzner E, Marth C, Widschwendter M and Reed SI. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002; 62(16):4535-4539.
6. Siu KT, Rosner MR and Minella AC. An integrated view of cyclin E function and regulation. Cell Cycle. 2012; 11(1):57-64.
7. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O and Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 2001; 413(6853):316-322.
8. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW and Elledge SJ. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001; 294(5540):173-177.
9. Caldon CE, Sergio CM, Sutherland RL and Musgrove EA. Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells. Cell Cycle. 2013; 12(4):596-605.
10. Welcker M, Orian A, Grim JE, Eisenman RN and Clurman BE. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol. 2004; 14(20):1852- 1857.
11. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN and Clurman BE. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004; 101(24):9085-9090.
12. Popov N, Herold S, Llamazares M, Schulein C and Eilers M. Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle. 2007; 6(19):2327- 2331.
13. Britton S, Salles B and Calsou P. c-MYC protein is degraded in response to UV irradiation. Cell Cycle. 2008; 7(1):63-70.
14. Nateri AS, Riera-Sans L, Da Costa C and Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science. 2004; 303(5662):1374-1378.
15. Rajagopalan H and Lengauer C. hCDC4 and genetic instability in cancer. Cell Cycle. 2004; 3(6):693-694.
16. Wei W, Jin J, Schlisio S, Harper JW and Kaelin WG, Jr. The v-Jun point mutation allows c-Jun to escape GSK3- dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005; 8(1):25-33.
17. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW and Wei W. Mcl-1 ubiquitination and destruction. Oncotarget. 2011; 2(3):239-244.
18. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, Xiao Y, Christie AL, Aster J, Settleman J, Gygi SP, Kung AL, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011; 471(7336):104-109.
19. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont LD, Kaminker JS, O'Rourke KM, Pujara K, Kohli PB, Johnson AR, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011; 471(7336):110-114.
20. Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH and Wei W. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012; 586(10):1409-1418.
21. Fryer CJ, White JB and Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell. 2004; 16(4):509-520.
22. Cheng Y and Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 2012; 31(1- 2):75-87.
23. Min SH, Lau AW, Lee TH, Inuzuka H, Wei S, Huang P, Shaik S, Lee DY, Finn G, Balastik M, Chen CH, Luo M, Tron AE, Decaprio JA, Zhou XZ, Wei W, et al. Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell. 2012; 46(6):771-783.
24. Xu Y, Sengupta T, Kukreja L and Minella AC. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem. 2010; 285(45):34439-34446.
25. Li J, Guo Y, Liang X, Sun M, Wang G, De W and Wu W. MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol. 2012; 138(5):763-774.
26. Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Akbari Moqadam F, Oude Vrielink JA, Agami R, Den Boer ML, Grander D and Sangfelt O. MiRNA-27a controls FBW7/ hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle. 2011; 10(13):2172-2183.
27. Spruck C. miR-27a regulation of SCF(Fbw7) in cell division control and cancer. Cell Cycle. 2011; 10(19):3232- 3233.
28. Finkin S, Aylon Y, Anzi S, Oren M and Shaulian E. Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy. Oncogene. 2008; 27(32):4411-4421.
29. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and Nakayama KI. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. Embo J. 2004; 23(10):2116-2125.
30. Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, Shibata K, Nakamura S, Kikuchi A and Kitagawa M. Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene. 2009; 28(25):2393- 2405.
31. Kitagawa K, Kotake Y, Hiramatsu Y, Liu N, Suzuki S, Nakamura S, Kikuchi A and Kitagawa M. GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Cell Div. 2010; 5:27.
32. Kanei-Ishii C, Nomura T, Takagi T, Watanabe N, Nakayama KI and Ishii S. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)- induced degradation. J Biol Chem. 2008; 283(45):30540- 30548.
33. Cassavaugh JM, Hale SA, Wellman TL, Howe AK, Wong C and Lounsbury KM. Negative regulation of HIF-1alpha by an FBW7-mediated degradation pathway during hypoxia. J Cell Biochem. 2011; 112(12):3882-3890.
34. Flugel D, Gorlach A and Kietzmann T. Glycogen synthase kinase-3beta regulates cell growth, migration and angiogenesis via Fbw7 and USP-28-dependent degradation of hypoxia-inducible factor-1alpha. Blood. 2011.
35. Liu N, Li H, Li S, Shen M, Xiao N, Chen Y, Wang Y, Wang W, Wang R, Wang Q, Sun J and Wang P. The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem. 2010; 285(24):18858- 18867.
36. Zhao D, Zheng HQ, Zhou Z and Chen C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 2010; 70(11):4728-4738.
37. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR and Sun SY. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 2009; 69(23):8967-8976.
38. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R and Balmain A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008; 321(5895):1499-1502.
39. Tan M, Zhao Y, Kim SJ, Liu M, Jia L, Saunders TL, Zhu Y and Sun Y. SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev Cell. 2011; 21(6):1062-1076.
40. Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, Mahon K, Harper JW, Schwartz RJ and Elledge SJ. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci U S A. 2004; 101(10):3338-3345.
41. Tsunematsu R, Nakayama K, Oike Y, Nishiyama M, Ishida N, Hatakeyama S, Bessho Y, Kageyama R, Suda T and Nakayama KI. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem. 2004; 279(10):9417-9423.
42. Biswas M, Phan D, Watanabe M and Chan JY. The Fbw7 tumor suppressor regulates nuclear factor E2-related factor 1 transcription factor turnover through proteasomemediated proteolysis. J Biol Chem. 2011; 286(45):39282- 39289.
43. Perez-Benavente B and Farras R. Regulation of GSK3beta- FBXW7-JUNB axis. Oncotarget. 2013; 4(7):956-957.
44. Perez-Benavente B, Garcia JL, Rodriguez MS, Pineda- Lucena A, Piechaczyk M, Font de Mora J and Farras R. GSK3-SCF(FBXW7) targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase. Oncogene. 2013; 32(17):2189-2199.
45. Punga T, Bengoechea-Alonso MT and Ericsson J. Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem. 2006; 281(35):25278-25286.
46. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW and Ericsson J. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005; 1(6):379-391.
47. Fukushima H, Matsumoto A, Inuzuka H, Zhai B, Lau AW, Wan L, Gao D, Shaik S, Yuan M, Gygi SP, Jimi E, Asara JM, Nakayama K, Nakayama KI and Wei W. SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. Cell Rep. 2012; 1(5):434-443.
48. Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O'Connor O, Hoffmann A, Elenitoba-Johnson KS and Pagano M. Fbxw7alpha-and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol. 2012; 14(4):375-385.
49. Lochab S, Pal P, Kapoor I, Kanaujiya JK, Sanyal S, Behre G and Trivedi AK. E3 ubiquitin ligase Fbw7 negatively regulates granulocytic differentiation by targeting G-CSFR for degradation. Biochim Biophys Acta. 2013; 1833(12):2639-2652.
50. Wang Z, Fukushima H, Gao D, Inuzuka H, Wan L, Lau AW, Liu P and Wei W. The two faces of FBW7 in cancer drug resistance. Bioessays. 2011; 33(11):851-859.
51. Wang Z, Inuzuka H, Fukushima H, Wan L, Gao D, Shaik S, Sarkar FH and Wei W. Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. EMBO Rep. 2012; 13(1):36-43.
52. Conaway RC and Conaway JW. Function and regulation of the Mediator complex. Curr Opin Genet Dev. 2011; 21(2):225-230.
53. Schiano C, Casamassimi A, Rienzo M, de Nigris F, Sommese L and Napoli C. Involvement of Mediator complex in malignancy. Biochim Biophys Acta. 2014; 1845(1):66-83.
54. Napoli C, Sessa M, Infante T and Casamassimi A. Unraveling framework of the ancestral Mediator complex in human diseases. Biochimie. 2012; 94(3):579-587.
55. Kato Y, Habas R, Katsuyama Y, Naar AM and He X. A component of the ARC/Mediator complex required for TGF beta/Nodal signalling. Nature. 2002; 418(6898):641-646.
56. Yang F, Vought BW, Satterlee JS, Walker AK, Jim Sun ZY, Watts JL, DeBeaumont R, Saito RM, Hyberts SG, Yang S, Macol C, Iyer L, Tjian R, van den Heuvel S, Hart AC, Wagner G, et al. An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature. 2006; 442(7103):700-704.
57. Chen W, Rogatsky I and Garabedian MJ. MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol Endocrinol. 2006; 20(3):560-572.
58. Malik S, Wallberg AE, Kang YK and Roeder RG. TRAP/ SMCC/mediator-dependent transcriptional activation from DNA and chromatin templates by orphan nuclear receptor hepatocyte nuclear factor 4. Mol Cell Biol. 2002; 22(15):5626-5637.
59. Grontved L, Madsen MS, Boergesen M, Roeder RG and Mandrup S. MED14 tethers mediator to the N-terminal domain of peroxisome proliferator-activated receptor gamma and is required for full transcriptional activity and adipogenesis. Mol Cell Biol. 2010; 30(9):2155-2169.
60. Geng F, Wenzel S and Tansey WP. Ubiquitin and proteasomes in transcription. Annu Rev Biochem. 2012; 81:177-201.
61. Collins GA and Tansey WP. The proteasome: a utility tool for transcription? Curr Opin Genet Dev. 2006; 16(2):197-202.
62. Davis MA, Larimore EA, Fissel BM, Swanger J, Taatjes DJ and Clurman BE. The SCF-Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator. Genes Dev. 2013; 27(2):151-156.
63. Tetreault MP, Yang Y and Katz JP. Kruppel-like factors in cancer. Nat Rev Cancer. 2013; 13(10):701-713.
64. Limame R, Op de Beeck K, Lardon F, De Wever O and Pauwels P. Kruppel-like factors in cancer progression: three fingers on the steering wheel. Oncotarget. 2013.
65. Humbert M, Halter V, Shan D, Laedrach J, Leibundgut EO, Baerlocher GM, Tobler A, Fey MF and Tschan MP. Deregulated expression of Kruppel-like factors in acute myeloid leukemia. Leuk Res. 2011; 35(7):909-913.
66. McConnell BB and Yang VW. Mammalian Kruppellike factors in health and diseases. Physiol Rev. 2010; 90(4):1337-1381.
67. Ghaleb AM and Yang VW. The Pathobiology of Kruppellike Factors in Colorectal Cancer. Curr Colorectal Cancer Rep. 2008; 4(2):59-64.
68. Taniguchi H, Jacinto FV, Villanueva A, Fernandez AF, Yamamoto H, Carmona FJ, Puertas S, Marquez VE, Shinomura Y, Imai K and Esteller M. Silencing of Kruppellike factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene. 2012; 31(15):1988-1994.
69. Xie P, Tang Y, Shen S, Wang Y, Xing G, Yin Y, He F and Zhang L. Smurf1 ubiquitin ligase targets Kruppel-like factor KLF2 for ubiquitination and degradation in human lung cancer H1299 cells. Biochem Biophys Res Commun. 2011; 407(1):254-259.
70. Wang R, Wang Y, Liu N, Ren C, Jiang C, Zhang K, Yu S, Chen Y, Tang H, Deng Q, Fu C, Li R, Liu M, Pan W and Wang P. FBW7 regulates endothelial functions by targeting KLF2 for ubiquitination and degradation. Cell Res. 2013; 23(6):803-819.
71. Baud V and Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009; 8(1):33-40.
72. Ben-Neriah Y and Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011; 12(8):715-723.
73. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441(7092):431-436.
74. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Moris F and Fernandez-Luna JL. The NFkappaB pathway: a therapeutic target in glioblastoma. Oncotarget. 2011; 2(8):646-653.
75. Demchenko YN and Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget. 2010; 1(1):59-68.
76. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012; 12(2):121-132.
77. DiDonato JA, Mercurio F and Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012; 246(1):379-400.
78. Walsby E, Pearce L, Burnett AK, Fegan C and Pepper C. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget. 2012; 3(5):525-534.
79. Arabi A, Ullah K, Branca RM, Johansson J, Bandarra D, Haneklaus M, Fu J, Aries I, Nilsson P, Den Boer ML, Pokrovskaja K, Grander D, Xiao G, Rocha S, Lehtio J and Sangfelt O. Proteomic screen reveals Fbw7 as a modulator of the NF-kappaB pathway. Nat Commun. 2012; 3:976.
80. Touw IP, Palande K and Beekman R. Granulocyte colonystimulating factor receptor signaling: implications for G-CSF responses and leukemic progression in severe congenital neutropenia. Hematol Oncol Clin North Am. 2013; 27(1):61-73, viii.
81. Kumar J, Fraser FW, Riley C, Ahmed N, McCulloch DR and Ward AC. Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer. Br J Cancer. 2014; 110(1):133-145.
82. Morris KT, Khan H, Ahmad A, Weston LL, Nofchissey RA, Pinchuk IV and Beswick EJ. G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. Br J Cancer. 2014; 110(5):1211-1220.
83. Chakraborty A and Guha S. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology. 2007; 69(6):1210-1215.
84. Yang X, Liu F, Xu Z, Chen C, Wu X, Li G and Li J. Expression of granulocyte colony stimulating factor receptor in human colorectal cancer. Postgrad Med J. 2005; 81(955):333-337.
85. Kunter G, Woloszynek JR and Link DC. A truncation mutant of Csf3r cooperates with PML-RARalpha to induce acute myeloid leukemia in mice. Exp Hematol. 2011; 39(12):1136-1143.
86. Kindwall-Keller TL, Druhan LJ, Ai J, Hunter MG, Massullo P, Loveland M and Avalos BR. Role of the proteasome in modulating native G-CSFR expression. Cytokine. 2008; 43(2):114-123.
87. Ai J, Druhan LJ, Loveland MJ and Avalos BR. G-CSFR ubiquitination critically regulates myeloid cell survival and proliferation. PLoS One. 2008; 3(10):e3422.
88. Kimura T, Gotoh M, Nakamura Y and Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 2003; 94(5):431-436.
89. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 2004; 432(7018):775-779.
90. Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R and Sterneck E. The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J. 2010; 29(24):4106-4117.
91. Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH and Chen YQ. Downregulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med. 2010.
92. Pei D, Zhang Y and Zheng J. Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget. 2012; 3(3):228-235.
93. Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P and Mahdi AA. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget. 2011; 2(12):948-957.
94. Muller PA and Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013; 15(1):2-8.
95. Wade M, Li YC and Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013; 13(2):83-96.
96. Cheok CF, Verma CS, Baselga J and Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011; 8(1):25-37.
97. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012; 12(9):613-626.
98. Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009; 9(12):862-873.
99. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003; 3(2):102-109.
100. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-848.
101. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH and Mohammad RM. Network modeling of MDM2 inhibitoroxaliplatin combination reveals biological synergy in wtp53 solid tumors. Oncotarget. 2011; 2(5):378-392.
102. Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S, Yang D, Sarkar FH and Mohammad RM. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011; 30(1):117-126.
103. Wang Y and Zhou BP. FBW7-Aurora B-p53 feedback loop regulates mitosis and cell growth. Cell Cycle. 2012; 11(22):4113-4114.
104. Liu Y, Huang Y, Wang Z, Li X, Louie A, Wei G and Mao JH. Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. Aging (Albany NY). 2013; 5(2):111-119.
105. Tsukada J, Yoshida Y, Kominato Y and Auron PE. The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highlyregulated system for gene regulation. Cytokine. 2011; 54(1):6-19.
106. Balamurugan K and Sterneck E. The many faces of C/ EBPdelta and their relevance for inflammation and cancer. Int J Biol Sci. 2013; 9(9):917-933.
107. Yu X, Si J, Zhang Y and Dewille JW. CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation. Cancer Cell Int. 2010; 10:48.
108. Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H and Koeffler HP. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res. 2005; 65(11):4762-4768.
109. Tang D, Sivko GS and DeWille JW. Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors. Breast Cancer Res Treat. 2006; 95(2):161-170.
110. Pawar SA, Sarkar TR, Balamurugan K, Sharan S, Wang J, Zhang Y, Dowdy SF, Huang AM and Sterneck E. C/ EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc Natl Acad Sci U S A. 2010; 107(20):9210-9215.
111. Roysarkar T, Sharan S, Wang J, Pawar SA, Cantwell CA, Johnson PF, Morrison DK, Wang JM and Sterneck E. Identification of a Src Tyrosine Kinase/SIAH2 E3 Ubiquitin Ligase Pathway That Regulates C/EBPdelta Expression and Contributes to Transformation of Breast Tumor Cells. Mol Cell Biol. 2012; 32(2):320-332.
112. Welcker M, Larimore EA, Frappier L and Clurman BE. Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol. 2011; 31(6):1214-1224.
113. Liao P, Wang W, Shen M, Pan W, Zhang K, Wang R, Chen T, Chen Y, Chen H and Wang P. A positive feedback loop between EBP2 and c-Myc regulates rDNA transcription, cell proliferation, and tumorigenesis. Cell Death Dis. 2014; 5:e1032.
114. Welcker M and Clurman BE. The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4. J Biol Chem. 2005; 280(9):7654-7658.
115. Driver JA and Lu KP. Pin1: a new genetic link between Alzheimer's disease, cancer and aging. Curr Aging Sci. 2010; 3(3):158-165.
116. Lu KP and Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 2007; 8(11):904-916.
117. Lu KP, Finn G, Lee TH and Nicholson LK. Prolyl cis-trans isomerization as a molecular timer. Nat Chem Biol. 2007; 3(10):619-629.
118. Xu GG and Etzkorn FA. Pin1 as an anticancer drug target. Drug News Perspect. 2009; 22(7):399-407.
119. Wulf G, Finn G, Suizu F and Lu KP. Phosphorylationspecific prolyl isomerization: is there an underlying theme? Nat Cell Biol. 2005; 7(5):435-441.
120. Lee TH, Pastorino L and Lu KP. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med. 2011; 13:e21.
121. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011; 20(1):79-91.
122. Lee TH, Chen CH, Suizu F, Huang P, Schiene-Fischer C, Daum S, Zhang YJ, Goate A, Chen RH, Zhou XZ and Lu KP. Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol Cell. 2011; 42(2):147-159.
123. Atkinson GP, Nozell SE, Harrison DK, Stonecypher MS, Chen D and Benveniste EN. The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma. Oncogene. 2009; 28(42):3735-3745.
124. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 2008; 68(15):6109-6117.
125. Ranganathan P, Weaver KL and Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011; 11(5):338-351.
126. Wang Z, Li Y and Sarkar FH. Notch signaling proteins: legitimate targets for cancer therapy. Curr Protein Pept Sci. 2010; 11(6):398-408.
127. Wang Z, Li Y, Kong D and Sarkar FH. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010; 11(6):745-751.
128. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D and Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010; 1806(2):258-267.
129. Wang Z, Li Y, Banerjee S and Sarkar FH. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 2008; 28(6A):3621-3630.
130. Radtke F and Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003; 3(10):756-767.
131. Li Y, Ma J, Qian X, Wu Q, Xia J, Miele L, Sarkar FH and Wang Z. Regulation of EMT by Notch signaling pathway in tumor progression. Curr Cancer Drug Targets. 2013; 13(9):957-962.
132. Capaccione KM and Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013; 34(7):1420-1430.
133. Espinoza I and Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther. 2013; 139(2):95-110.
134. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol. 2012; 727:305-319.
135. Piazzi G, Fini L, Selgrad M, Garcia M, Daoud Y, Wex T, Malfertheiner P, Gasbarrini A, Romano M, Meyer RL, Genta RM, Fox JG, Boland CR, Bazzoli F and Ricciardiello L. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget. 2011; 2(12):1291-1301.
136. Chen X, Stoeck A, Lee SJ, Shih Ie M, Wang MM and Wang TL. Jagged1 expression regulated by Notch3 and Wnt/betacatenin signaling pathways in ovarian cancer. Oncotarget. 2010; 1(3):210-218.
137. Wang X, Fu Y, Chen X, Ye J, Lu B, Ye F, Lu W and Xie X. The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study. J Cancer Res Clin Oncol. 2010; 136(7):989-996.
138. Liu J, Ye F, Chen H, Lu W, Zhou C and Xie X. Expression of differentiation associated protein Hes1 and Hes5 in cervical squamous carcinoma and its precursors. Int J Gynecol Cancer. 2007; 17(6):1293-1299.
139. Sancho R, Blake SM, Tendeng C, Clurman BE, Lewis J and Behrens A. Fbw7 repression by hes5 creates a feedback loop that modulates notch-mediated intestinal and neural stem cell fate decisions. PLoS Biol. 2013; 11(6):e1001586.
140. Gulino A, Di Marcotullio L and Screpanti I. The multiple functions of Numb. Exp Cell Res. 2010; 316(6):900-906.
141. Yan B. Numb--from flies to humans. Brain Dev. 2010; 32(4):293-298.
142. Pece S, Confalonieri S, P RR and Di Fiore PP. NUMBing down cancer by more than just a NOTCH. Biochim Biophys Acta. 2011; 1815(1):26-43.
143. Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G, Pece S and Di Fiore PP. NUMB controls p53 tumour suppressor activity. Nature. 2008; 451(7174):76-80.
144. Misquitta-Ali CM, Cheng E, O'Hanlon D, Liu N, McGlade CJ, Tsao MS and Blencowe BJ. Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol. 2011; 31(1):138-150.
145. Jiang X, Xing H, Kim TM, Jung Y, Huang W, Yang HW, Song S, Park PJ, Carroll RS and Johnson MD. Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. Stem Cells. 2012; 30(7):1313-1326.
146. Dhami GK, Liu H, Galka M, Voss C, Wei R, Muranko K, Kaneko T, Cregan SP, Li L and Li SS. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. Mol Cell. 2013; 50(4):565-576.
147. Sczaniecka M, Gladstone K, Pettersson S, McLaren L, Huart AS and Wallace M. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem. 2012; 287(17):14052-14068.
148. McGill MA, Dho SE, Weinmaster G and McGlade CJ. Numb regulates post-endocytic trafficking and degradation of Notch1. J Biol Chem. 2009; 284(39):26427-26438.
149. McGill MA and McGlade CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem. 2003; 278(25):23196-23203.
150. Chen J, Xu J, Zhao W, Hu G, Cheng H, Kang Y, Xie Y and Lu Y. Characterization of human LNX, a novel ligand of Numb protein X that is downregulated in human gliomas. Int J Biochem Cell Biol. 2005; 37(11):2273-2283.
151. Susini L, Passer BJ, Amzallag-Elbaz N, Juven-Gershon T, Prieur S, Privat N, Tuynder M, Gendron MC, Israel A, Amson R, Oren M and Telerman A. Siah-1 binds and regulates the function of Numb. Proc Natl Acad Sci U S A. 2001; 98(26):15067-15072.
152. Kasinski AL and Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011; 11(12):849-864.
153. Ling H, Fabbri M and Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013; 12(11):847-865.
154. van Kouwenhove M, Kedde M and Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011; 11(9):644-656.
155. Garzon R, Marcucci G and Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-789.
156. Schwarzenbach H, Nishida N, Calin GA and Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-156.
157. Zhang Z, Liu S, Shi R and Zhao G. miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-tomesenchymal transition. Cancer Genet. 2011; 204(9):486-491.
158. Tang W, Zhu J, Su S, Wu W, Liu Q, Su F and Yu F. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One. 2012; 7(12):e51702.
159. Mertens-Talcott SU, Chintharlapalli S, Li X and Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007; 67(22):11001-11011.
160. Guttilla IK and White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009; 284(35):23204-23216.
161. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG and Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008; 76(5):582-588.
162. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L and Zheng X. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010; 55(9):2545-2551.
163. Liu T, Tang H, Lang Y, Liu M and Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 2009; 273(2):233-242.
164. Acunzo M, Romano G, Palmieri D, Lagana A, Garofalo M, Balatti V, Drusco A, Chiariello M, Nana-Sinkam P and Croce CM. Cross-talk between MET and EGFR in nonsmall cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A. 2013; 110(21):8573-8578.
165. Ma Y, Yu S, Zhao W, Lu Z and Chen J. miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett. 2010; 298(2):150-158.
166. Tang W, Yu F, Yao H, Cui X, Jiao Y, Lin L, Chen J, Yin D, Song E and Liu Q. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene. 2013.
167. Wang Q, Li DC, Li ZF, Liu CX, Xiao YM, Zhang B, Li XD, Zhao J, Chen LP, Xing XM, Tang SF, Lin YC, Lai YD, Yang P, Zeng JL, Xiao Q, et al. Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. Oncogene. 2011; 30(36):3875-3886.
168. Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, Sikandar SS, Gumus ZH and Lipkin SM. miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov. 2012; 2(6):540-553.
169. Haneklaus M, Gerlic M, O'Neill LA and Masters SL. miR-223: infection, inflammation and cancer. J Intern Med. 2013; 274(3):215-226.
170. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezgin O, Altintas E and Tiftik EN. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep. 2014.
171. Liang L, Zhu J, Zaorsky NG, Deng Y, Wu X, Liu Y, Liu F, Cai G, Gu W, Shen L and Zhang Z. MicroRNA-223 Enhances Radiation Sensitivity of U87MG Cells In Vitro and In Vivo by Targeting Ataxia Telangiectasia Mutated. Int J Radiat Oncol Biol Phys. 2014; 88(4):955-960.
172. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C and Lin D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011; 50(2):136-142.
173. Chiaretti S, Messina M, Tavolaro S, Zardo G, Elia L, Vitale A, Fatica A, Gorello P, Piciocchi A, Scappucci G, Bozzoni I, Fozza C, Candoni A, Guarini A and Foa R. Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. Haematologica. 2010; 95(7):1114-1121.
174. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B and J OL. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008; 7:35.
175. Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and Baba H. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer. 2012; 106(1):182-188.
176. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM and Baffa R. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007; 25(5):387-392.
177. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, Han S, Nie Y, Chen X, Zhao Q, Ding J, Wu K, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 2011; 9(7):824-833.
178. Li S, Li Z, Guo F, Qin X, Liu B, Lei Z, Song Z, Sun L, Zhang HT, You J and Zhou Q. miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci. 2011; 18:24.
179. Streppel MM, Pai S, Campbell NR, Hu C, Yabuuchi S, Canto MI, Wang JS, Montgomery EA and Maitra A. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res. 2013; 19(15):4067-4078.
180. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF and Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 2008; 135(1):257-269.
181. Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T, Khan AA, Setti M, Rondou P, Vandenberghe P, Delabesse E, Benoit Y, Socci NB, Leslie CS, Van Vlierberghe P, Speleman F, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet. 2011; 43(7):673-678.
182. Wu C, Li M, Hu C and Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep. 2014; 41(3):1257-1266.
183. Zhao H, Wang Y, Yang L, Jiang R and Li W. MiR-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2014; 385(1-2):207-213.
184. Xu FX, Su YL, Zhang H, Kong JY, Yu H and Qian BY. Prognostic Implications for High Expression of MiR-25 in Lung Adenocarcinomas of Female Non-smokers. Asian Pac J Cancer Prev. 2014; 15(3):1197-1203.
185. Li Q, Zou C, Han Z, Xiao H, Wei H, Wang W, Zhang L, Zhang X, Tang Q, Zhang C, Tao J, Wang X and Gao X. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett. 2013; 335(1):168-174.
186. Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM and Fusco A. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 2012; 97(5):E710-718.
187. Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang Z, Tan F, Tan X, Zhou F, Sun J, Sun N, Gao Y, Shao K, Li N, Qiu B and He J. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2012; 421(4):640-645.
188. Fang WK, Liao LD, Li LY, Xie YM, Xu XE, Zhao WJ, Wu JY, Zhu MX, Wu ZY, Du ZP, Wu BL, Xie D, Guo MZ, Xu LY and Li EM. Down-regulated desmocollin-2 promotes cell aggressiveness through redistributing adherens junctions and activating beta-catenin signalling in oesophageal squamous cell carcinoma. J Pathol. 2013; 231(2):257-270.
189. Zhang H, Zuo Z, Lu X, Wang L, Wang H and Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012; 27(2):594-598.
190. Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR and Mott JL. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology. 2012; 55(2):465-475.
191. Lu D, Davis MP, Abreu-Goodger C, Wang W, Campos LS, Siede J, Vigorito E, Skarnes WC, Dunham I, Enright AJ and Liu P. MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. PLoS One. 2012; 7(8):e40938.
192. Zhang J, Li S, Yan Q, Chen X, Yang Y, Liu X and Wan X. Interferon-beta Induced microRNA-129-5p Down-Regulates HPV-18 E6 and E7 Viral Gene Expression by Targeting SP1 in Cervical Cancer Cells. PLoS One. 2013; 8(12):e81366.
193. Yu X, Song H, Xia T, Han S, Xiao B, Luo L, Xi Y and Guo J. Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene. 2013; 532(1):87-93.
194. Brest P, Lassalle S, Hofman V, Bordone O, Gavric Tanga V, Bonnetaud C, Moreilhon C, Rios G, Santini J, Barbry P, Svanborg C, Mograbi B, Mari B and Hofman P. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011; 18(6):711-719.
195. Liu Y, Hei Y, Shu Q, Dong J, Gao Y, Fu H, Zheng X and Yang G. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One. 2012; 7(4):e35800.
196. Zhi F, Cao X, Xie X, Wang B, Dong W, Gu W, Ling Y, Wang R, Yang Y and Liu Y. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One. 2013; 8(2):e56718.
197. Hasler R, Jacobs G, Till A, Grabe N, Cordes C, Nikolaus S, Lao K, Schreiber S and Rosenstiel P. Microbial pattern recognition causes distinct functional micro-RNA signatures in primary human monocytes. PLoS One. 2012; 7(2):e31151.
198. Huang H, Ma L, Li J, Yu Y, Zhang D, Wei J, Jin H, Xu D, Gao J and Huang C. NF-kappaB1 inhibits c-Myc protein degradation through suppression of FBW7 expression. Oncotarget. 2013.
199. Wang Z, Liu Y, Zhang P, Zhang W, Wang W, Curr K, Wei G and Mao JH. FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7. Oncotarget. 2013; 4(12):2476-2486.
200. Esquejo RM, Jeon TI and Osborne TF. Lipid-cell cycle nexus: SREBP regulates microRNAs targeting Fbxw7. Cell Cycle. 2014; 13(3):339-340.
201. Jeon TI, Esquejo RM, Roqueta-Rivera M, Phelan PE, Moon YA, Govindarajan SS, Esau CC and Osborne TF. An SREBP-responsive microRNA operon contributes to a regulatory loop for intracellular lipid homeostasis. Cell Metab. 2013; 18(1):51-61.
202. Sionov RV, Netzer E and Shaulian E. Differential regulation of FBXW7 isoforms by various stress stimuli. Cell Cycle. 2013; 12(22):3547-3554.
203. Ma J, Cheng L, Liu H, Zhang J, Shi Y, Zeng F, Miele L, Sarkar FH, Xia J and Wang Z. Genistein down-regulates miR-223 expression in pancreatic cancer cells. Curr Drug Targets. 2013; 14(10):1150-1156.